antivir
drug
resist
develop
new
virus
emerg
press
need
develop
strategi
rapidli
develop
antivir
therapeut
use
phosphospecif
flow
cytometri
assess
perturb
mani
differ
cellular
signal
pathway
treatment
drug
combin
highli
effect
block
herp
simplex
viru
type
infect
discov
two
antivir
drug
combin
act
distinct
signal
pathway
either
phosphoryl
block
infect
focus
upregul
phosphoryl
infect
subsequ
find
ribavirin
antagon
upregul
phosphoryl
go
show
kinas
inhibitor
block
replic
vitro
vivo
anim
model
infect
overal
use
unbias
analysi
cellular
signal
pathway
treatment
antivir
drug
combin
discov
novel
antivir
drug
target
infect
outcom
approach
present
highlight
import
analyz
antivir
drug
modul
cellular
pathogeninduc
signal
method
discov
new
drug
therapi
target
one
approach
new
therapeut
drug
discoveri
base
efficaci
drug
one
particular
target
outcom
stop
infect
limit
diseas
patholog
howev
potenti
side
effect
offlabel
indic
often
found
clinic
trial
postmarket
drug
safeti
monitor
consequ
approach
drug
discoveri
often
lead
unexpect
problem
misfir
delay
block
signific
advanc
techniqu
determin
best
drug
combin
drug
optim
treat
diseas
without
use
convent
drug
screen
approach
need
rapid
effici
translat
medicin
lee
et
al
sun
et
al
develop
target
therapi
focu
key
signal
pathway
lead
patholog
avoid
bystand
perturb
physiolog
cell
possibl
look
therapeut
drug
combin
impact
cell
use
unbias
analysi
cellular
signal
bendal
et
al
bodenmil
et
al
schweizer
zhang
treatment
differ
diseas
state
combin
multipl
drug
use
achiev
better
therapeut
result
reduc
impact
drug
resist
sustain
high
efficaci
low
toxic
often
lower
dose
individu
drug
compon
use
drug
combin
well
document
cancer
infecti
diseas
therapi
allazikani
et
al
art
hazuda
georg
et
al
therapeut
drug
combin
work
simultan
control
sever
cellular
pathway
complex
network
system
previou
studi
ding
et
al
two
combin
antivir
drug
one
combin
rich
interferon
one
rich
ribavirin
determin
due
abil
inhibit
herp
simplex
viru
type
infect
combin
identifi
feedback
system
control
fsc
techniqu
use
unbias
search
base
outcom
drug
combin
treatment
identifi
mani
unexpect
drug
combin
offer
desir
therapeut
output
wong
et
al
howev
due
focu
output
fsc
search
methodolog
give
inform
cellular
signal
pathway
stimul
drug
combin
mechanist
reason
behind
efficaci
optim
drug
combin
studi
use
phosphospecif
flow
cytometri
phosphoflow
understand
chang
cellular
signal
use
potent
antivir
drug
combin
stimuli
phosphoryl
dephosphoryl
protein
kinas
phosphatas
part
essenti
regulatori
network
drive
phenotyp
function
cell
tissu
organ
especi
exposur
drug
biolog
therapeut
sach
et
al
advanc
phosphoflow
made
studi
phosphoproteom
level
possibl
krutzik
nolan
use
phosphoflow
monitor
multipl
indic
cellular
physiolog
allow
us
determin
drug
combin
affect
intric
cellular
signal
simultan
interrog
distinct
signal
node
within
treat
cell
insight
afford
us
phosphoflow
analysi
drug
combin
diseas
state
may
allow
us
better
design
specif
therapeut
modul
activ
diseaserel
kinas
phosphatas
krutzik
et
al
bodenmil
et
al
antivir
repres
class
drug
develop
often
focus
singular
outcom
limit
viral
infect
howev
side
effect
potenti
offlabel
secondari
indic
use
drug
often
discov
drug
use
fda
approv
prime
exampl
viru
well
studi
regard
antivir
therapi
frequent
infect
human
lead
diseas
rang
mild
mucocutan
lesion
life
threaten
infect
especi
elderli
immunocompromis
patient
whitley
roizman
character
abil
develop
latenc
neuron
sensori
ganglia
lytic
outbreak
often
requir
drug
therapi
knickelbein
et
al
although
extens
research
effort
made
unveil
mechan
infect
new
aspect
pathogenesi
frequent
discov
tognarelli
et
al
sauerbrei
johnston
corey
standard
therapi
hsv
manag
includ
acyclovir
acv
compound
develop
extens
use
acv
expect
antivir
therapeut
led
resist
acv
increasingli
report
morfin
thouvenot
piret
boivin
futur
clinic
efficaci
acv
assess
therapi
increas
efficaci
reduc
resist
potenti
improv
pharmacokinet
undoubtedli
benefit
clinic
outcom
jame
prichard
combinatori
drug
often
provid
better
efficaci
reduc
individu
drug
dose
compar
treatment
singl
drug
silva
et
al
nowaksliwinska
et
al
weiss
et
al
ding
et
al
mention
two
distinct
drug
combin
identifi
fsc
techniqu
mixtur
acv
either
ribavirin
rib
interferon
ifn
could
effect
inhibit
infect
ding
et
al
though
drug
combin
effect
reduc
infect
underli
mechan
particular
drug
combin
potent
fulli
explor
studi
infect
cell
treat
either
ribrich
drug
combin
ifnrich
drug
combin
compar
sidebysid
use
phosphoflow
technolog
determin
drug
combin
affect
cellular
signal
network
focus
one
set
pathway
cellular
signal
use
unbias
approach
look
across
variou
signal
node
cell
better
understand
antivir
mechan
two
drug
combin
directli
identifi
cellular
signal
pathway
critic
control
replic
studi
demonstr
power
use
approach
analyz
drug
combin
translat
find
importantli
also
directli
translat
find
signal
chang
involv
infect
directli
target
chang
antivir
therapi
vitro
investig
carri
nih
cell
cell
line
deriv
mous
embryo
fibroblast
nih
cell
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
antibiot
penicillin
streptomycin
prepar
quantiz
conduct
previous
describ
ding
et
al
virus
dilut
dmem
multipl
infect
moi
purchas
pbl
interferon
sourc
piscataway
nj
rib
acv
purchas
calbiochem
san
diego
ca
dmem
purchas
cellgro
manassa
va
penicillin
streptomycin
obtain
gibco
grand
island
ny
paraformaldehyd
pfa
purchas
electron
microscopi
scienc
hatfield
pa
phosphat
buffer
salin
pb
bought
emd
rockland
plate
tube
purchas
bd
falcon
san
jose
ca
base
previou
work
ding
et
al
follow
five
drug
combin
appli
compar
current
studi
tabl
high
dose
ifn
acv
optimala
optimalaa
high
dose
rib
acv
optimalb
low
dose
ifn
acv
subopta
low
dose
ifn
rib
suboptb
individu
drug
combin
administr
alon
combin
time
duplic
treatment
sampl
four
time
point
h
collect
phosphoflow
perform
previous
describ
krutzik
et
al
briefli
cell
without
treatment
fix
formaldehyd
final
concentr
permeabil
pure
methanol
wash
twice
stain
medium
pb
contain
bovin
serum
albumin
sodium
azid
final
stain
phosphospecif
antibodi
stain
medium
antibodi
akt
also
known
protein
kinas
b
erk
extracellular
signalrel
kinas
jnk
cjun
ntermin
kinas
cjun
mitogenactiv
protein
kinaseactiv
protein
kinas
nuclear
factor
mitogenactiv
protein
kinas
ribosom
protein
signal
transduc
activ
transcript
flow
cytometri
perform
bd
facscanto
ii
flow
cytomet
acquisit
data
analyz
use
flowjo
softwar
gener
median
fluoresc
intens
mfi
valu
phosphoprotein
treatment
group
median
valu
export
microsoft
excel
analysi
experi
done
isotyp
control
determin
background
stain
addit
experi
done
triplic
data
present
singl
flow
cytometri
plot
repres
three
experi
data
triplic
convert
bar
graph
averag
data
plot
error
bar
repres
standard
error
valid
causeeffect
relationship
signal
infect
use
kinas
inhibitor
evalu
effect
drug
combin
downregul
signal
pathway
three
dose
compar
rib
acv
cell
infect
time
drug
administ
also
examin
effect
treatment
pakt
perk
rsk
use
phosphoflow
vivo
compound
treatment
stimul
perform
femal
ko
strain
mice
anim
handl
perform
accord
univers
california
lo
angel
ucla
anim
research
committe
guidelin
anim
monitor
chang
health
regularli
mous
receiv
either
pfuml
pb
vehicl
via
vagin
administr
day
infect
allow
occur
h
post
viru
administr
first
vagin
lavag
collect
h
post
infect
day
follow
immedi
drug
treatment
via
vagin
administr
second
vagin
lavag
collect
h
postinfect
h
postfirstround
drug
treatment
day
follow
immedi
drug
treatment
via
vagin
administr
third
vagin
lavag
collect
h
postinfect
h
postsecondround
drug
treatment
day
viral
copi
number
vagin
lavag
quantifi
plaqu
assay
describ
assess
optimalb
efficaci
twentyseven
mice
randomli
distribut
three
group
contain
nine
mice
one
group
untreat
one
treat
acv
ngml
one
treat
drug
combin
optimalb
evalu
rsk
inhibitor
eighteen
mice
divid
two
group
untreat
control
group
treat
group
dose
appli
treat
group
plaqu
assay
perform
vero
cell
monolay
lavag
serial
dilut
eight
time
dmem
ratio
process
ml
lavag
dilut
ad
vero
cell
monolay
viru
absorpt
allow
proceed
h
gentl
shake
everi
min
absorpt
excess
viru
remov
three
wash
dmem
ml
agar
overlay
medium
ad
top
vero
cell
monolay
plaqu
start
form
agar
overlay
remov
cell
monolay
stain
crystal
violet
plaqu
count
microscop
bar
graph
produc
base
averag
three
experiment
data
point
statist
differ
determin
use
ttest
viral
level
day
day
untreat
sampl
fold
tabl
well
individu
drug
remind
high
dose
ifn
acv
optimala
optimalaa
high
dose
rib
acv
optimalb
low
dose
ifn
acv
subopta
low
dose
ifn
rib
suboptb
drug
treatment
indic
bottom
panel
sampl
collect
h
drug
stimul
although
phosphoprotein
examin
sampl
pakt
perk
pjnk
pcjun
show
complet
panel
shown
supplementari
fig
b
comparison
signal
h
individu
drug
treatment
indic
ifn
upregul
signal
rib
downregul
signal
c
comparison
two
optim
drug
combin
treatment
show
ifnrich
treatment
upregul
signal
ribrich
treatment
downregul
signal
experiment
data
shown
repres
data
three
independ
experi
flow
cytometri
histogram
colorcod
heatmap
black
unchang
shade
yellow
denot
increas
quantit
plot
b
c
shown
supplement
fig
chang
viru
level
day
versu
day
day
versu
day
better
understand
therapeut
drug
combin
abl
inhibit
replic
use
phosphoflow
simultan
monitor
phosphoryl
state
cellular
signal
node
akt
erk
jnk
cjun
individu
cell
upon
drug
stimul
chose
differ
signal
node
highlight
key
signal
transduct
cascad
modul
would
lead
direct
chang
state
cell
system
robust
enough
track
chang
cellular
physiolog
indic
chang
cellular
signal
induc
differ
drug
combin
provid
definit
insight
cell
affect
drug
individu
optim
combin
look
panel
phosphoprotein
individu
drug
combin
administr
alon
combin
duplic
time
sampl
collect
four
time
point
post
simul
h
use
approach
abl
discern
exact
chang
treat
cell
signatur
optim
drug
combin
overview
phosphoprotein
panel
shown
supplementari
fig
indic
protein
phosphoryl
state
unaffect
cell
treat
drug
combin
howev
analysi
panel
signal
node
reveal
level
phosphoryl
phosphoryl
notic
regul
treatment
differ
drug
combin
fig
sixteen
hour
drug
treatment
found
stimul
individu
reveal
expect
interferon
includ
induc
upregul
dosedepend
manner
fig
left
panel
yellow
histogram
addit
see
drug
individu
caus
minim
chang
high
level
protein
except
higher
dose
ribavirin
fig
right
panel
black
histogram
optim
combin
follow
key
individu
drug
ifnrich
treatment
optimala
induc
increas
level
induc
obviou
chang
fig
convers
ribrich
treatment
optimalb
decreas
level
induc
obviou
chang
fig
drug
combin
discov
effect
block
replic
ding
et
al
two
drug
combin
seem
chang
cellular
signal
distinct
way
base
result
describ
next
focus
phosphoryl
state
drug
treatment
cell
monitor
time
show
upregul
dosedepend
manner
earli
h
extend
h
drug
treatment
fig
b
contrast
ad
drug
combin
contain
rib
lower
dosedepend
manner
signal
instant
marker
rib
decreas
h
drug
treatment
fig
plot
signal
sidebysid
along
time
cours
instant
longlast
marker
ifn
wherea
later
period
marker
rib
fig
better
understand
drug
induc
chang
cellular
signal
network
would
lead
limit
replic
next
system
evalu
chang
phosphoprotein
panel
viral
infect
treat
drug
combin
compar
uninfect
cell
treat
drug
combin
alon
cell
preinfect
follow
drug
treatment
provid
realist
model
studi
chang
cellular
physiolog
optim
drug
combin
treatment
drug
treatment
would
almost
alway
take
place
infect
detect
fig
use
engin
express
gfp
green
fluoresc
protein
way
track
replic
within
infect
cell
allow
us
distinguish
chang
cellular
signal
induc
infect
singl
cell
level
sampl
infect
done
multipl
infect
moi
hsv
h
cell
treat
drug
condit
equival
gfp
levelspercentag
h
drug
treatment
fig
gfp
level
hsv
sampl
low
across
treatment
indic
viral
infect
still
progress
major
cell
remain
uninfect
neither
ifnrich
ribrich
treatment
lower
level
viral
infect
instantan
manner
fig
h
drug
treatment
gfp
level
hsv
sampl
increas
extens
throughout
cell
popul
indic
viral
infect
abl
infect
whole
cell
popul
time
frame
model
viru
infect
prior
drug
treatment
drug
combin
optimalb
ribrich
combin
outperform
optimala
ifnrich
combin
viral
inhibit
h
post
treatment
although
optimala
optimalb
combin
identifi
drugviru
coinfect
model
ding
et
al
drug
combin
optimala
bare
reduc
viral
infect
level
cell
infect
viru
prior
treatment
fig
may
due
previou
work
use
viral
coinfectiontreat
model
determin
optim
drug
combin
result
fig
suggest
ifn
directli
erad
viru
alreadi
infect
cell
instead
ifn
inhibit
viral
infect
target
uninfect
cell
prepar
avoid
viral
invas
line
known
biolog
mechan
ifn
viral
infect
begun
cell
popul
ifn
could
reduc
level
viral
infect
contrast
optimalb
ribrich
combin
effect
studi
cell
infect
prior
drug
treatment
result
indic
rib
directli
target
viral
replic
insid
cell
differ
phosphoprotein
signal
becam
complex
h
treatment
fig
pakt
regul
variou
extent
differ
drug
combin
particular
rib
treatment
led
decreas
level
reduct
viral
burden
fig
level
diminish
infect
cell
level
recov
ifn
treatment
fig
infect
decreas
level
wherea
block
infect
acv
contain
treatment
increas
signal
fig
induc
infect
cell
acv
treatment
reduc
level
baselin
fig
acv
contain
treatment
reduc
level
appear
induc
pakt
level
posit
popul
fig
overal
viral
infect
present
phosphoprotein
chang
becam
complex
howev
signific
chang
phosphoryl
statu
drug
combin
optimala
still
signific
chang
phosphoryl
statu
drug
combin
optimalb
still
correl
ifn
statu
infect
wide
report
part
known
biolog
ifn
howev
lack
agreement
mechan
rib
high
efficaci
ribrich
drug
combin
block
encourag
us
focu
investig
correl
among
rib
level
infect
x
ding
et
al
antivir
research
signal
identifi
marker
ifn
rich
treatment
rib
rich
treatment
b
instant
longlast
marker
ifn
treatment
activ
avail
earli
h
drug
stimul
continu
h
ifn
drug
treatment
c
signal
identifi
marker
rib
rich
treatment
ifn
rich
treatment
signal
instant
marker
laterperiod
marker
rib
treatment
level
chang
h
drug
treatment
e
quantif
signal
sampl
treat
optimala
optimalb
indic
signal
optimala
specif
optimalb
specif
unit
drug
ng
ml
remind
high
dose
ifn
acv
optimala
optimalaa
high
dose
rib
acv
optimalb
low
dose
ifn
acv
subopta
low
dose
ifn
rib
suboptb
part
e
data
plot
mean
standard
deviat
experiment
data
shown
repres
data
three
independ
experi
confirm
correl
among
rib
signal
infect
obtain
initi
screen
investig
state
cellular
signal
cell
simultan
treat
drug
combin
infect
fig
order
allow
viral
infect
propag
adequ
focus
time
point
h
cell
treat
drug
combin
infect
model
optimala
optimalb
profoundli
reduc
infect
compar
unstimul
control
fig
result
line
conclus
previous
publish
find
ding
et
al
compar
infect
level
fig
level
fig
infect
induc
increas
level
fold
rib
ribcontain
drug
combin
reduc
percent
infect
level
follow
similar
pattern
percent
infect
plot
level
reveal
viral
infect
follow
loglinear
relationship
level
fig
thu
use
unbias
screen
monitor
chang
cellular
phosphoryl
state
allow
us
identifi
key
chang
cellular
physiolog
connect
efficaci
given
antivir
drug
combin
antivir
effect
understood
modul
phosphoryl
state
critic
target
control
replic
sought
valid
causeeffect
relationship
signal
infect
use
kinas
inhibitor
evalu
effect
downregul
pathway
replic
look
viral
replic
h
treatment
slightli
decreas
gfp
level
sampl
rib
profoundli
decreas
viral
infect
level
fig
also
examin
effect
treatment
pakt
perk
rsk
present
rib
show
gener
signal
regul
across
multipl
pathway
viral
stimul
howev
longer
result
dramat
signal
regul
result
show
infect
could
overcom
chang
induc
low
dose
howev
treatment
result
gener
decreas
signal
across
multipl
pathway
rib
appear
much
specif
signal
regul
significantli
downregul
fig
infect
pakt
found
involv
viral
infect
inhibit
process
remind
high
dose
ifn
acv
optimala
optimalaa
high
dose
rib
acv
optimalb
low
dose
ifn
acv
subopta
low
dose
ifn
rib
suboptb
experiment
data
shown
repres
data
three
independ
experi
flow
cytometri
histogram
colorcod
heatmap
black
unchang
shade
yellow
denot
increas
quantit
b
shown
supplement
fig
quantit
plot
c
shown
supplement
fig
gfp
level
pakt
level
level
level
level
level
red
arrow
supplement
fig
e
f
indic
optimalb
ribavirin
treatment
across
analysi
import
note
broad
spectrum
modul
signal
pathway
drug
may
lead
druginduc
toxic
therefor
possibl
could
toxic
rib
even
though
toxic
obviou
base
observ
cellular
morpholog
vitro
studi
supplementari
fig
induc
toxic
mtt
assay
concentr
use
studi
supplementari
fig
inhibit
viru
absent
effect
dose
viru
present
fig
viru
present
downregul
furthermor
hsv
infect
present
obvious
reduc
viral
infect
level
infect
level
diminish
therefor
regul
signal
dosedepend
manner
uninfect
cell
treatment
inhibit
hsv
infect
high
dose
concord
chang
viral
infect
ultim
goal
system
use
phosphoflow
better
understand
drug
therapi
affect
cellular
physiolog
quickli
develop
target
therapeut
modal
treat
diseas
studi
use
mous
model
vagin
infect
way
assess
vivo
efficaci
drug
combin
previous
discov
addit
act
proof
principl
platform
determin
key
signal
node
manipul
therapi
diseas
fig
depict
setup
model
vagin
infect
mice
ensur
anim
model
could
use
evalu
inhibit
efficaci
vivo
first
test
acv
alon
drug
combin
optimalb
ribrich
treatment
mice
treat
acv
show
decreas
viral
load
especi
day
remark
mice
treat
drug
combin
optimalb
level
lower
untreat
mice
day
fig
result
indic
anim
model
could
appli
effect
vivo
model
examin
inhibit
efficaci
drug
treatment
test
vivo
effect
use
anim
model
fig
mice
treat
show
signific
viral
reduct
compar
untreat
group
day
howev
treat
group
show
fold
viral
reduct
compar
untreat
group
day
fig
compar
fold
chang
level
eg
level
day
divid
day
level
level
day
divid
day
level
benefit
treatment
limit
replic
becam
much
clearer
especi
unlik
drug
combin
optimalb
start
show
strong
effect
day
antivir
effect
delay
day
fig
analysi
altern
cellular
signal
induc
one
drug
combin
drug
diseas
state
rapidli
elucid
intric
chang
cellular
signal
crucial
determin
therapeut
appli
drug
proper
balanc
therapeut
outcom
potenti
side
effect
phosphoflow
technolog
robust
tool
monitor
mani
cellular
signal
pathway
modul
drug
treatment
georg
et
al
hildebrand
kubatzki
coppin
et
al
use
technolog
one
rapidli
interrog
state
key
signal
node
divers
cellular
pathway
focus
work
chang
phosphoryl
state
panel
key
signal
node
repres
host
cell
preinfect
receiv
drug
treatment
h
signal
alter
becam
complex
compar
host
cell
treat
drug
without
viru
rib
reduc
level
viral
burden
b
signal
block
infect
cell
recov
ifn
treatment
c
level
decreas
treatment
wherea
block
infect
increas
signal
induc
infect
cell
wherea
acv
contain
treatment
reduc
level
baselin
e
acv
treatment
reduc
level
appear
induc
pakt
level
posit
popul
remind
high
dose
ifn
acv
optimala
experiment
data
shown
repres
data
three
independ
experi
x
ding
et
al
antivir
research
major
cellular
process
could
alter
drug
treatment
use
present
studi
focus
infect
infect
well
control
current
avail
antivir
must
develop
altern
therapeut
strategi
due
sever
reason
reason
includ
appear
antivir
resist
strain
possibl
induc
enhanc
diseas
immunocompromis
individu
lack
effect
vaccin
analyz
cellular
signal
system
level
determin
antivir
drug
combin
modul
mani
differ
pathway
discov
differ
molecular
signatur
assay
phosphoflow
result
reveal
infect
target
use
antivir
modul
one
two
pathway
combin
contain
rib
caus
chang
phosphoryl
wherea
ifncontain
combin
lead
chang
phosphoryl
wellknown
cellular
induc
antivir
state
horvath
darnel
liu
et
al
antivir
state
effici
block
viral
growth
thu
make
sens
marker
antivir
activ
impact
modul
phosphoryl
would
viral
replic
wellunderstood
idea
replic
either
induc
requir
upregul
level
phosphoryl
block
heighten
level
phosphoryl
rib
suffici
block
replicaiton
use
find
focu
phosphoryl
new
target
develop
therapeut
infect
use
focu
use
small
molecul
inhibitor
kinas
reduc
phosphorul
therebi
mimic
efficaci
one
drug
combin
lower
phosphoryl
went
show
could
effect
block
replic
anim
model
drug
combin
optimala
optimalb
profoundli
reduc
infect
compar
unstimul
control
cotreat
model
data
point
averag
data
three
experiment
standard
deviat
flow
cytometri
histogram
colorcod
heatmap
black
unchang
shade
yellow
denot
increas
c
drug
treatment
versu
percent
infect
data
point
averag
data
three
experiment
standard
deviat
drug
treatment
versu
level
show
similar
pattern
viral
infect
e
infect
level
phosphoryl
level
follow
loglinear
correl
data
point
averag
data
three
experiment
standard
deviat
remind
high
dose
ifn
acv
optimala
optimalaa
high
dose
rib
acv
optimalb
low
dose
ifn
acv
subopta
low
dose
ifn
rib
suboptb
experiment
data
shown
repres
data
three
independ
experi
part
c
e
data
plot
mean
standard
deviat
part
e
correl
coeffici
r
display
one
well
studi
virus
known
intrigu
analysi
cellular
signal
modul
infect
cell
use
unbias
approach
discov
phosphoryl
new
target
antivir
target
given
import
protein
control
ribosom
translat
studi
replic
benefit
chang
common
method
manipul
cellular
translat
among
differ
virus
need
ruvinski
meyuha
could
efficaci
rib
convey
via
chang
induc
virus
theme
manipul
virus
common
viral
diseas
phosphoryl
modul
may
new
class
antivir
efficaci
phosphoryl
inhibit
reduc
replic
anim
model
vagin
infect
show
import
understand
chang
cellular
signal
effect
block
viral
infect
howev
result
studi
reveal
even
without
infect
rib
directli
lower
level
phosphoryl
find
import
underscor
regul
phosphoryl
occur
cell
without
viral
infect
consequ
consequ
chang
phosphoryl
state
key
ribosom
protein
drug
may
immens
see
obviou
chang
cellular
morpholog
chang
cell
viabil
assess
mtt
assay
cell
treat
suggest
minim
cellular
toxic
induc
howev
investig
impact
cellular
physiolog
warrant
order
develop
effect
counter
measur
side
effect
may
induc
type
antivir
rib
becom
goto
drug
antivir
therapi
especi
look
target
replic
virus
option
treatment
one
time
rib
major
treatment
hepat
c
viru
infect
ribindepend
therapi
becom
commonplac
clinic
kish
et
al
rib
remain
first
line
antivir
therapi
virus
world
stage
includ
merscov
middl
east
respiratori
syndromecorona
viru
lassa
fever
viru
zika
viru
kamiyama
et
al
carrillobustamant
et
al
chong
et
al
howev
differ
mechan
action
may
work
everi
viru
rib
effect
treat
includ
nucleosid
base
level
chang
catastroph
error
induct
cell
te
et
al
crotti
et
al
conclus
use
phosphoflow
technolog
evalu
possibl
mechan
therapeut
drug
combin
elucid
drug
combin
modul
cellular
signal
design
better
antivir
therapeut
specif
abl
identifi
phosphoryl
key
signal
node
involv
kinas
inhibitor
inhibit
display
riblik
behavior
b
show
gener
decreas
signal
across
multipl
pathway
particularli
c
appear
decreas
signal
pathway
basal
activ
inhibit
viru
present
effect
dose
viru
present
present
requir
high
show
inhibit
flow
cytometri
histogram
colorcod
heatmap
accord
scale
b
experiment
data
shown
repres
data
three
independ
experi
part
c
p
valu
p
valu
quantit
plot
b
shown
supplement
fig
pakt
level
level
level
level
replic
demonstr
therapeut
drug
combin
effect
block
replic
modul
signal
node
block
replic
extend
find
develop
proof
principl
mous
model
vagin
infect
target
phosphoryl
directli
kinas
inhibitor
efficaci
target
phosphoryl
step
show
use
analysi
cellular
signal
modul
determin
new
efficaci
antivir
drug
target
xd
dmjr
cmh
gpn
dj
wrote
manuscript
xd
pok
aag
yz
dj
conduct
experi
xd
yz
dmjr
dj
analyz
data
xd
pok
aag
gc
cmh
gpn
dj
design
experi
